|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Verve Therapeutics, Inc. (VERV) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
89,140,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0 - $0 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Verve Therapeutics is a genetic medicines company developing an approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. Co.'s primary product candidate, VERVE-101, is designed to turn off the PCSK9 gene in the liver. PCSK9 is a validated target that plays a critical role in controlling blood low-density lipoprotein cholesterol through its regulation of the low-density lipoprotein receptor. Co.'s second program is designed to turn off the ANGPTL3 gene in the liver. ANGPTL3 is a main regulator of cholesterol and triglyceride metabolism.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
1,876,000 |
Total Buy Value |
$0 |
$0 |
$0 |
$18,475,760 |
Total People Bought |
0 |
0 |
0 |
2 |
Total Buy Transactions |
0 |
0 |
0 |
2 |
Total Shares Sold |
24,054 |
24,054 |
24,609 |
26,677 |
Total Sell Value |
$99,824 |
$99,824 |
$102,954 |
$121,772 |
Total People Sold |
6 |
6 |
6 |
6 |
Total Sell Transactions |
6 |
6 |
7 |
9 |
End Date |
2025-03-16 |
2024-12-13 |
2024-06-14 |
2023-06-15 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Nickerson Joan |
Chief Administrative Officer |
|
2025-04-02 |
4 |
S |
$4.15 |
$11,525 |
D/D |
(2,777) |
17,420 |
|
- |
|
Politi Jason |
Chief Technical Ops. Off. |
|
2025-04-02 |
4 |
S |
$4.15 |
$13,425 |
D/D |
(3,235) |
14,226 |
|
- |
|
Lister Troy |
Chief Scientific Officer |
|
2025-04-02 |
4 |
S |
$4.15 |
$9,084 |
D/D |
(2,189) |
6,952 |
|
- |
|
Ashe Andrew D. |
See Remarks |
|
2025-04-02 |
4 |
S |
$4.15 |
$11,126 |
D/D |
(2,681) |
348,828 |
|
- |
|
Kathiresan Sekar |
Chief Executive Officer |
|
2025-04-02 |
4 |
S |
$4.15 |
$40,761 |
D/D |
(9,822) |
346,686 |
|
- |
|
Dorval Allison |
Chief Financial Officer |
|
2025-04-02 |
4 |
S |
$4.15 |
$13,903 |
D/D |
(3,350) |
13,280 |
|
- |
|
Nickerson Joan |
Chief Administrative Officer |
|
2025-04-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,315 |
20,197 |
|
- |
|
Politi Jason |
Chief Technical Ops. Off. |
|
2025-04-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,815 |
17,461 |
|
- |
|
Lister Troy |
Chief Scientific Officer |
|
2025-04-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,340 |
9,141 |
|
- |
|
Ashe Andrew D. |
See Remarks |
|
2025-04-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,000 |
351,509 |
|
- |
|
Kathiresan Sekar |
Chief Executive Officer |
|
2025-04-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
33,000 |
356,508 |
|
- |
|
Dorval Allison |
Chief Financial Officer |
|
2025-04-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,250 |
16,630 |
|
- |
|
Kathiresan Sekar |
Chief Executive Officer |
|
2024-12-04 |
4 |
GA |
$0.00 |
$0 |
I/I |
30,000 |
110,997 |
|
- |
|
Kathiresan Sekar |
Chief Executive Officer |
|
2024-12-04 |
4 |
GD |
$0.00 |
$0 |
D/D |
30,000 |
323,508 |
|
- |
|
Dorval Allison |
Chief Financial Officer |
|
2024-12-02 |
4 |
S |
$5.64 |
$3,130 |
D/D |
(555) |
5,380 |
|
- |
|
Dorval Allison |
Chief Financial Officer |
|
2024-11-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,875 |
5,935 |
|
- |
|
Kathiresan Sekar |
Chief Executive Officer |
|
2024-06-28 |
4 |
OE |
$2.87 |
$86,100 |
D/D |
30,000 |
351,128 |
|
- |
|
Ashe Andrew D. |
See Remarks |
|
2024-05-14 |
4 |
B |
$6.26 |
$475,760 |
D/D |
76,000 |
342,509 |
0.01 |
- |
|
Nickerson Joan |
Chief Administrative Officer |
|
2024-04-02 |
4 |
S |
$8.24 |
$12,475 |
D/D |
(1,514) |
8,659 |
|
- |
|
Nickerson Joan |
Chief Administrative Officer |
|
2024-04-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,315 |
10,173 |
|
- |
|
Alphabet Inc. |
|
|
2023-12-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,800,000 |
|
- |
|
Yeshwant Krishna |
|
|
2023-12-01 |
4 |
B |
$10.00 |
$18,000,000 |
I/I |
1,800,000 |
1,800,000 |
0.01 |
- |
|
Dorval Allison |
Chief Financial Officer |
|
2023-11-29 |
4 |
S |
$11.45 |
$6,343 |
D/D |
(554) |
4,060 |
|
- |
|
Dorval Allison |
Chief Financial Officer |
|
2023-11-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,875 |
4,614 |
|
- |
|
Nickerson Joan |
Chief Administrative OfficerOf |
|
2023-02-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,494 |
|
- |
|
117 Records found
|
|
Page 1 of 5 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|